MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ
1.027
+0.088
+9.36%
After Hours: 1.020 -0.007 -0.66% 18:48 06/02 EDT
OPEN
0.9897
PREV CLOSE
0.9389
HIGH
1.030
LOW
0.9500
VOLUME
17.09K
TURNOVER
0
52 WEEK HIGH
6.50
52 WEEK LOW
0.8300
MARKET CAP
5.19M
P/E (TTM)
-0.2344
1D
5D
1M
3M
1Y
5Y
Qualigen Therapeutics Inc: Current report
Press release · 05/19 08:21
Qualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61M
Seeking Alpha · 05/16 13:02
BRIEF-Qualigen Therapeutics, Inc. Reports Financial Results And Corporate Update For Quarter Ending March 31, 2023
Reuters · 05/16 12:46
Qualigen Therapeutics Q1 EPS $(0.78) Up From $(1.20) YoY, Sales $1.61M Miss $2.00M Estimate
Benzinga · 05/16 12:06
-- Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M
-- Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M
MT Newswires · 05/16 08:08
Qualigen Therapeutics Inc: Quarterly report
Press release · 05/15 16:13
Watching Qualigen Therapeutics; Zacks Small-Cap Research Sets $5 Price Valuation
Benzinga · 05/12 14:13
BRIEF-Qualigen Therapeutics Inc Gets Nasdaq Notified For Regained Compliance
Reuters · 05/05 21:27
More
About QLGN
Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.